-
Presenters to provide first look at data from REIMAGINE trials of cagrilintide/semaglutide for type 2 diabetes management
John B. Buse, MD, PhD, and other researchers will share study results and a broad understanding of amylin, from the hormone’s biology to potential translation to clinical care via phase 3 trials.
-
Experts to discuss AIDING results for automated insulin delivery in the hospital
Francisco Pasquel, MD, MPH, and other experts will share findings from this study evaluating automated insulin delivery initiated in the hospital compared with daily injections in people with type 1 or type 2 diabetes.
-
Panel discussion to explore stem cell-derived beta cell therapy for type 1 diabetes
Sanjoy Dutta, PhD, Jay Skyler, MD, and other panelists will share insights on advances in the use of manufactured islets and what it might take to achieve widespread clinical use.
-
Trending topics in diabetes and obesity research and care highlight the 2026 Scientific Sessions program
Experts from across the globe will offer new perspectives on obesity, artificial intelligence, liver disease, behavioral health, women’s health, nutrition, new technology, and other trending topics in diabetes this June in New Orleans.
-
New clinical trial results to debut daily in New Orleans
Investigators will present high-impact results for type 1 diabetes, type 2 diabetes, and obesity in several clinical trial sessions. Glucagon-like peptide-1 (GLP-1)-based therapies—including dual and triple agonists, oral agents, and longer acting formulations—will be a recurring topic.